Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease

Jean Guillaume Dillinger, Vincent Maher, Cristiana Vitale, Patrick Henry, Damien Logeart, Stephane Manzo Silberman, Guillaume Allée, Bernard I. Levy

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Treatment of hypertensive patients with β-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering brachial blood pressure could increase central blood pressure, explaining the increased cardiovascular risk reported with β-blocker. We describe a randomized, double-blind study to explore whether heart rate reduction with the If inhibitor ivabradine had an impact on central blood pressure. We included 12 normotensive patients with stable coronary artery disease, heart rate ≥70 bpm (sinus rhythm), and stable background β-blocker therapy. Patients received ivabradine 7.5 mg BID or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm; P=0.0010). There was no relevant between-group difference in change in central aortic systolic blood pressure (-4.0±9.6 versus +2.4±12.0 mm Hg; P=0.13) or augmentation index (-0.8±10.0% versus +0.3±7.6%; P=0.87). Treatment with ivabradine was associated with a modest increase in left ventricular ejection time (+18.5±17.8 versus +2.8±19.3 ms; P=0.074) and a prolongation of diastolic perfusion time (+215.6±105.3 versus -3.0±55.8 ms with placebo; P=0.0005). Consequently, ivabradine induced a pronounced increase in Buckberg index, an index of myocardial viability (+39.3±27.6% versus -2.5±13.5% with placebo; P=0.0015). In conclusion, heart rate reduction with ivabradine does not increase central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion index.

Original languageEnglish
Pages (from-to)1138-1144
Number of pages7
JournalHypertension
Volume66
Issue number6
DOIs
Publication statusPublished - Dec 1 2015

Fingerprint

ivabradine
Coronary Artery Disease
Arterial Pressure
Perfusion
Heart Rate
Blood Pressure
Placebos
Manometry
Therapeutics
Double-Blind Method
Cross-Over Studies
Antihypertensive Agents
Arm

Keywords

  • blood pressure
  • cardiovascular diseases
  • coronary artery disease
  • heart rate
  • ivabradine

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. / Dillinger, Jean Guillaume; Maher, Vincent; Vitale, Cristiana; Henry, Patrick; Logeart, Damien; Silberman, Stephane Manzo; Allée, Guillaume; Levy, Bernard I.

In: Hypertension, Vol. 66, No. 6, 01.12.2015, p. 1138-1144.

Research output: Contribution to journalArticle

Dillinger, Jean Guillaume ; Maher, Vincent ; Vitale, Cristiana ; Henry, Patrick ; Logeart, Damien ; Silberman, Stephane Manzo ; Allée, Guillaume ; Levy, Bernard I. / Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease. In: Hypertension. 2015 ; Vol. 66, No. 6. pp. 1138-1144.
@article{1c282ca40caf4841874c66fce368c302,
title = "Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease",
abstract = "Treatment of hypertensive patients with β-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering brachial blood pressure could increase central blood pressure, explaining the increased cardiovascular risk reported with β-blocker. We describe a randomized, double-blind study to explore whether heart rate reduction with the If inhibitor ivabradine had an impact on central blood pressure. We included 12 normotensive patients with stable coronary artery disease, heart rate ≥70 bpm (sinus rhythm), and stable background β-blocker therapy. Patients received ivabradine 7.5 mg BID or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm; P=0.0010). There was no relevant between-group difference in change in central aortic systolic blood pressure (-4.0±9.6 versus +2.4±12.0 mm Hg; P=0.13) or augmentation index (-0.8±10.0{\%} versus +0.3±7.6{\%}; P=0.87). Treatment with ivabradine was associated with a modest increase in left ventricular ejection time (+18.5±17.8 versus +2.8±19.3 ms; P=0.074) and a prolongation of diastolic perfusion time (+215.6±105.3 versus -3.0±55.8 ms with placebo; P=0.0005). Consequently, ivabradine induced a pronounced increase in Buckberg index, an index of myocardial viability (+39.3±27.6{\%} versus -2.5±13.5{\%} with placebo; P=0.0015). In conclusion, heart rate reduction with ivabradine does not increase central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion index.",
keywords = "blood pressure, cardiovascular diseases, coronary artery disease, heart rate, ivabradine",
author = "Dillinger, {Jean Guillaume} and Vincent Maher and Cristiana Vitale and Patrick Henry and Damien Logeart and Silberman, {Stephane Manzo} and Guillaume All{\'e}e and Levy, {Bernard I.}",
year = "2015",
month = "12",
day = "1",
doi = "10.1161/HYPERTENSIONAHA.115.06091",
language = "English",
volume = "66",
pages = "1138--1144",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease

AU - Dillinger, Jean Guillaume

AU - Maher, Vincent

AU - Vitale, Cristiana

AU - Henry, Patrick

AU - Logeart, Damien

AU - Silberman, Stephane Manzo

AU - Allée, Guillaume

AU - Levy, Bernard I.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Treatment of hypertensive patients with β-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering brachial blood pressure could increase central blood pressure, explaining the increased cardiovascular risk reported with β-blocker. We describe a randomized, double-blind study to explore whether heart rate reduction with the If inhibitor ivabradine had an impact on central blood pressure. We included 12 normotensive patients with stable coronary artery disease, heart rate ≥70 bpm (sinus rhythm), and stable background β-blocker therapy. Patients received ivabradine 7.5 mg BID or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm; P=0.0010). There was no relevant between-group difference in change in central aortic systolic blood pressure (-4.0±9.6 versus +2.4±12.0 mm Hg; P=0.13) or augmentation index (-0.8±10.0% versus +0.3±7.6%; P=0.87). Treatment with ivabradine was associated with a modest increase in left ventricular ejection time (+18.5±17.8 versus +2.8±19.3 ms; P=0.074) and a prolongation of diastolic perfusion time (+215.6±105.3 versus -3.0±55.8 ms with placebo; P=0.0005). Consequently, ivabradine induced a pronounced increase in Buckberg index, an index of myocardial viability (+39.3±27.6% versus -2.5±13.5% with placebo; P=0.0015). In conclusion, heart rate reduction with ivabradine does not increase central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion index.

AB - Treatment of hypertensive patients with β-blockers reduces heart rate and decreases central blood pressure less than other antihypertensive drugs, implying that reducing heart rate without altering brachial blood pressure could increase central blood pressure, explaining the increased cardiovascular risk reported with β-blocker. We describe a randomized, double-blind study to explore whether heart rate reduction with the If inhibitor ivabradine had an impact on central blood pressure. We included 12 normotensive patients with stable coronary artery disease, heart rate ≥70 bpm (sinus rhythm), and stable background β-blocker therapy. Patients received ivabradine 7.5 mg BID or matched placebo for two 3-week periods with a crossover design and evaluation by aplanation tonometry. Treatment with ivabradine was associated with a significant reduction in resting heart rate after 3 weeks versus no change with placebo (-15.8±7.7 versus +0.3±5.8 bpm; P=0.0010). There was no relevant between-group difference in change in central aortic systolic blood pressure (-4.0±9.6 versus +2.4±12.0 mm Hg; P=0.13) or augmentation index (-0.8±10.0% versus +0.3±7.6%; P=0.87). Treatment with ivabradine was associated with a modest increase in left ventricular ejection time (+18.5±17.8 versus +2.8±19.3 ms; P=0.074) and a prolongation of diastolic perfusion time (+215.6±105.3 versus -3.0±55.8 ms with placebo; P=0.0005). Consequently, ivabradine induced a pronounced increase in Buckberg index, an index of myocardial viability (+39.3±27.6% versus -2.5±13.5% with placebo; P=0.0015). In conclusion, heart rate reduction with ivabradine does not increase central aortic blood pressure and is associated with a marked prolongation of diastolic perfusion time and an improvement in myocardial perfusion index.

KW - blood pressure

KW - cardiovascular diseases

KW - coronary artery disease

KW - heart rate

KW - ivabradine

UR - http://www.scopus.com/inward/record.url?scp=84947492585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947492585&partnerID=8YFLogxK

U2 - 10.1161/HYPERTENSIONAHA.115.06091

DO - 10.1161/HYPERTENSIONAHA.115.06091

M3 - Article

C2 - 26418022

AN - SCOPUS:84947492585

VL - 66

SP - 1138

EP - 1144

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 6

ER -